Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salmeterol/fluticasone propionate - DMK Pharmaceuticals

Next Previous
Drug Profile

Salmeterol/fluticasone propionate - DMK Pharmaceuticals

Alternative Names: APC 5000 DPI; APC-5000; Fluticasone propionate/salmeterol - DMK Pharmaceuticals; Salmeterol-xinafoate/fluticasone-propionate

Latest Information Update: 13 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Developer DMK Pharmaceuticals
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Sep 2023 Adamis Pharmaceuticals Corporation is now called DMK Pharmaceuticals
  • 19 Jan 2017 Phase-II development is ongoing in USA
  • 03 Aug 2016 Adamis has European patent for salmeterol/fluticasone propionate using DPI

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top